

**MERCK & CO., INC.**  
**FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS)**  
**(UNAUDITED)**  
**Table 3 - CONTINUING OPERATIONS**

	2021	2020					1Q	
	1Q	1Q	2Q	3Q	4Q	Full Year	Nom %	Ex-Exch %
<b>TOTAL SALES <sup>(1)</sup></b>	<b>\$10,627</b>	<b>\$10,288</b>	<b>\$9,353</b>	<b>\$10,929</b>	<b>\$10,948</b>	<b>\$41,518</b>	<b>3</b>	<b>2</b>
<b>PHARMACEUTICAL</b>	<b>9,238</b>	<b>8,905</b>	<b>8,178</b>	<b>9,714</b>	<b>9,813</b>	<b>36,610</b>	<b>4</b>	<b>16</b>
<b>Oncology</b>								
Keytruda	3,899	3,284	3,388	3,715	3,993	14,380	19	16
Alliance Revenue – Lynparza <sup>(2)</sup>	228	145	178	196	206	725	57	51
Alliance Revenue – Lenvima <sup>(2)</sup>	130	128	151	142	158	580	1	-1
<b>Vaccines <sup>(3)</sup></b>								
Gardasil / Gardasil 9	917	1,097	656	1,187	998	3,938	-16	-20
ProQuad / M-M-R II / Varivax	449	435	378	576	488	1,878	3	2
Pneumovax 23	171	256	117	375	339	1,087	-33	-36
RotaTeq	158	222	168	210	196	797	-29	-29
Vaqta	34	60	28	51	31	170	-43	-44
<b>Hospital Acute Care</b>								
Bridion	340	299	224	320	355	1,198	14	11
Prevymis	82	60	63	77	80	281	37	31
Noxafil	67	94	73	79	82	329	-29	-32
Primaxin	65	51	64	74	62	251	26	17
Candidas	57	55	43	50	65	213	4	1
Invanz	57	64	43	51	53	211	-12	-11
Zerbaxa	(8)	37	32	43	19	130	-121	-120
<b>Immunology</b>								
Simponi	214	215	191	209	223	838	0	-8
Remicade	85	88	73	82	88	330	-3	-9
<b>Neuroscience</b>								
Belsomra	79	79	84	81	83	327	0	-4
<b>Virology</b>								
Isentress / Isentress HD	209	245	196	205	211	857	-15	-15
<b>Cardiovascular</b>								
Alliance Revenue - Adempas <sup>(4)</sup>	74	53	79	83	65	281	38	38
Adempas <sup>(5)</sup>	55	56	57	55	53	220	-2	-10
<b>Diabetes <sup>(6)</sup></b>								
Januvia	809	774	854	821	857	3,306	5	2
Janumet	486	503	490	506	472	1,971	-3	-6
<b>Other Pharmaceutical <sup>(7)</sup></b>	<b>581</b>	<b>605</b>	<b>548</b>	<b>526</b>	<b>636</b>	<b>2,312</b>	<b>-4</b>	<b>*</b>
<b>ANIMAL HEALTH</b>	<b>1,418</b>	<b>1,214</b>	<b>1,101</b>	<b>1,220</b>	<b>1,168</b>	<b>4,703</b>	<b>17</b>	<b>15</b>
Livestock	819	739	648	758	794	2,939	11	9
Companion Animals	599	475	453	462	374	1,764	26	24
<b>Other Revenues <sup>(8)</sup></b>	<b>(29)</b>	<b>169</b>	<b>74</b>	<b>(5)</b>	<b>(33)</b>	<b>205</b>	<b>-117</b>	<b>-10</b>

\* 200% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

<sup>(1)</sup> Only select products are shown. Total sales represents sales for Continuing Operations

<sup>(2)</sup> Alliance Revenue represents Merck's share of profits, which are product sales net of cost of sales and commercialization costs.

<sup>(3)</sup> Total Vaccines sales were \$1,809 million in the first quarter of 2021 and \$2,155 million, \$1,418 million, \$2,521 million and \$2,163 million in the first, second, third and fourth quarters of 2020, respectively.

<sup>(4)</sup> Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.

<sup>(5)</sup> Net product sales in Merck's marketing territories.

<sup>(6)</sup> Total Diabetes sales were \$1,363 million in the first quarter of 2021 and \$1,353 million, \$1,418 million, \$1,405 million and \$1,412 million in the first, second, third and fourth quarters of 2020, respectively.

<sup>(7)</sup> Includes Pharmaceutical products not individually shown above.

<sup>(8)</sup> Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.

**MERCK & CO., INC.**  
**FRANCHISE / KEY PRODUCT SALES FIRST QUARTER 2021 (AMOUNTS IN MILLIONS)**  
**(UNAUDITED)**  
**Table 3a - CONTINUING OPERATIONS**

	Global			U.S.			International		
	1Q 2021	1Q 2020	% Change	1Q 2021	1Q 2020	% Change	1Q 2021	1Q 2020	% Change
<b>TOTAL SALES<sup>(1)</sup></b>	<b>\$10,627</b>	<b>\$10,288</b>	<b>3</b>	<b>\$4,732</b>	<b>\$4,716</b>		<b>\$5,895</b>	<b>\$5,572</b>	<b>6</b>
<b>PHARMACEUTICAL</b>	<b>9,238</b>	<b>8,905</b>	<b>4</b>	<b>4,294</b>	<b>4,308</b>		<b>4,944</b>	<b>4,598</b>	<b>8</b>
<b>Oncology</b>									
Keytruda	3,899	3,284	19	2,181	1,906	14	1,718	1,378	25
Alliance Revenue - Lynparza <sup>(2)</sup>	228	145	57	118	85	39	110	60	81
Alliance Revenue - Lenvima <sup>(2)</sup>	130	128	1	85	90	-5	44	38	17
<b>Vaccines<sup>(3)</sup></b>									
Gardasil / Gardasil 9	917	1,097	-16	313	461	-32	604	636	-5
ProQuad / M-M-R II / Varivax	449	435	3	333	333		117	102	14
Pneumovax 23	171	256	-33	73	182	-60	99	75	32
RotaTeq	158	222	-29	118	140	-16	41	82	-50
Vaqta	34	60	-43	25	30	-17	9	30	-70
<b>Hospital Acute Care</b>									
Bridion	340	299	14	167	143	17	173	157	10
Prevymis	82	60	37	35	26	33	47	33	41
Noxafil	67	94	-29	15	8	96	52	87	-40
Primaxin	65	51	26			-97	65	51	27
Candidas	57	55	4	3	3	-4	55	52	5
Invanz	57	64	-12	4	6	-26	52	59	-11
Zerbaxa	(8)	37	-121	(2)	20	-110	(6)	16	-135
<b>Immunology</b>									
Simponi	214	215					214	215	
Remicade	85	88	-3				85	88	-3
<b>Neuroscience</b>									
Belsomra	79	79		18	27	-33	61	53	17
<b>Virology</b>									
Isentress / Isentress HD	209	245	-15	71	75	-6	138	170	-19
<b>Cardiovascular</b>									
Alliance Revenue - Adempas <sup>(4)</sup>	74	53	38	68	49	40	6	5	22
Adempas <sup>(5)</sup>	55	56	-2				55	56	-2
<b>Diabetes<sup>(6)</sup></b>									
Januvia	809	774	5	348	355	-2	461	419	10
Janumet	486	503	-3	84	113	-26	401	390	3
<b>Other Pharmaceutical<sup>(7)</sup></b>	<b>581</b>	<b>605</b>	<b>-4</b>	<b>237</b>	<b>256</b>	<b>-7</b>	<b>343</b>	<b>346</b>	<b>-1</b>
<b>ANIMAL HEALTH</b>	<b>1,418</b>	<b>1,214</b>	<b>17</b>	<b>437</b>	<b>385</b>	<b>14</b>	<b>981</b>	<b>829</b>	<b>18</b>
Livestock	819	739	11	157	163	-4	662	576	15
Companion Animals	599	475	26	280	222	26	319	253	26
<b>Other Revenues<sup>(8)</sup></b>	<b>(29)</b>	<b>169</b>	<b>-117</b>	<b>1</b>	<b>23</b>	<b>-95</b>	<b>(30)</b>	<b>145</b>	<b>-121</b>

\* 200% or greater

Sum of U.S. plus international may not equal global due to rounding.

<sup>(1)</sup> Only select products are shown.

<sup>(2)</sup> Alliance Revenue represents Merck's share of profits, which are product sales net of cost of sales and commercialization costs.

<sup>(3)</sup> Total Vaccines sales were \$1,809 million in the first quarter of 2021 and \$2,155 million in the first quarter of 2020.

<sup>(4)</sup> Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.

<sup>(5)</sup> Net product sales in Merck's marketing territories.

<sup>(6)</sup> Total Diabetes sales were \$1,363 million in the first quarter of 2021 and \$1,353 million in the first quarter of 2020.

<sup>(7)</sup> Includes Pharmaceutical products not individually shown above.

<sup>(8)</sup> Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.

**MERCK & CO., INC.**  
**PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUED OPERATIONS (AMOUNTS IN MILLIONS)**  
**(UNAUDITED)**

**Table 3c - CONTINUED OPERATIONS**

	2021	2020					% Change
	1Q	1Q	2Q	3Q	4Q	Full Year	1Q
<b>TOTAL PHARMACEUTICAL <sup>(1)</sup></b>	<b>\$9,238</b>	<b>\$8,905</b>	<b>\$8,178</b>	<b>\$9,714</b>	<b>\$9,813</b>	<b>\$36,610</b>	<b>4</b>
<b>United States</b>	<b>4,294</b>	<b>4,308</b>	<b>3,958</b>	<b>4,842</b>	<b>4,903</b>	<b>18,010</b>	<b>0</b>
% Pharmaceutical Sales	46.5%	48.4%	48.4%	49.8%	50.0%	49.2%	
<b>Europe <sup>(2)</sup></b>	<b>2,276</b>	<b>2,116</b>	<b>1,855</b>	<b>2,171</b>	<b>2,314</b>	<b>8,455</b>	<b>8</b>
% Pharmaceutical Sales	24.6%	23.8%	22.7%	22.3%	23.6%	23.1%	
<b>China</b>	<b>688</b>	<b>628</b>	<b>600</b>	<b>764</b>	<b>670</b>	<b>2,661</b>	<b>10</b>
% Pharmaceutical Sales	7.4%	7.0%	7.3%	7.9%	6.8%	7.3%	
<b>Japan</b>	<b>607</b>	<b>561</b>	<b>601</b>	<b>648</b>	<b>704</b>	<b>2,514</b>	<b>8</b>
% Pharmaceutical Sales	6.6%	6.3%	7.4%	6.7%	7.2%	6.9%	
<b>Asia Pacific (other than China and Japan)</b>	<b>437</b>	<b>411</b>	<b>377</b>	<b>411</b>	<b>414</b>	<b>1,614</b>	<b>6</b>
% Pharmaceutical Sales	4.7%	4.6%	4.6%	4.2%	4.2%	4.4%	
<b>Eastern Europe/Middle East/Africa</b>	<b>357</b>	<b>353</b>	<b>309</b>	<b>289</b>	<b>251</b>	<b>1,199</b>	<b>1</b>
% Pharmaceutical Sales	3.9%	4.0%	3.8%	3.0%	2.6%	3.3%	
<b>Latin America</b>	<b>353</b>	<b>314</b>	<b>312</b>	<b>372</b>	<b>371</b>	<b>1,369</b>	<b>12</b>
% Pharmaceutical Sales	3.8%	3.5%	3.8%	3.8%	3.8%	3.7%	
<b>Canada</b>	<b>160</b>	<b>159</b>	<b>121</b>	<b>169</b>	<b>149</b>	<b>599</b>	<b>1</b>
% Pharmaceutical Sales	1.7%	1.8%	1.5%	1.7%	1.5%	1.6%	
<b>Other</b>	<b>66</b>	<b>55</b>	<b>45</b>	<b>48</b>	<b>37</b>	<b>189</b>	<b>20</b>
% Pharmaceutical Sales	0.7%	0.6%	0.6%	0.5%	0.4%	0.5%	

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

<sup>(1)</sup> Pharmaceutical sales represented sales based on Merck Continuing Operations (excluding Organon sales).

<sup>(2)</sup> Europe represents all European Union countries, the European Union accession markets and the United Kingdom.